Physician
Washington Regional Medical System
Washington Regional Medical System was paid $169K by Medicaid between Jan 2018 and Nov 2022, across 11 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoWASHINGTON REGIONAL MEDICAL SYSTEM
FAYETTEVILLE, AR 72703
FAYETTEVILLE, AR 72703
33aNPI1700297033assigned 05/08/2014
33bProvider typeGeneral Practice Physician
28Total paid$169K
24GClaims8,201
24DCodes billed11
24AFirst – last monthJan 2018 – Nov 2022
Compared with peers
Next to other General Practice Physician providers in Arkansas
Rank by total paid#10 of 39
Median peer was paid$49K
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,313 | $37K | |
| 2019 | 1,905 | $29K | |
| 2020 | 1,480 | $25K | |
| 2021 | 712 | $35K | |
| 2022 | 1,791 | $44K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 2,962 | 2,329 | $56K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 18% | 808 | 705 | $30K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 11% | 102 | 99 | $19K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 536 | 460 | $19K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 9.1% | 1,345 | 853 | $15K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 7.5% | 1,701 | 1,277 | $13K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 7.3% | 577 | 417 | $12K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.0% | 116 | 91 | $3K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 30 | 24 | $1K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 12 | 12 | $560.00 |
| 81003 | 0% | 12 | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHACKELFORD, JAMES (CEO)